A multi-center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and effects on arterial structure and function of ACZ885 (canakinumab) in patients with clinically evident atherosclerosis and either type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT)

ID Number 09-2089

Principal Investigator(s)
Zahi A Fayad

Department(s) or Division(s)

Research Entity
The Zena and Michael A. Wiener Cardiovascular Institute


The purpose of this study is to look at the safety and effectiveness of an investigational drug called ACZ885 (canakinumab) when used in people with documented Type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) with atherosclerotic vascular disease . We are interested in understanding if this investigational drug helps to stop the process that affects three important factors of the structure of blood vessels: 1) aortic distensibility (the ability of the blood vessel to stretch), 2) endothelial function (overall health of the lining of the arteries), and 3) plaque burden (how much narrowing of the arteries has occurred).

Contact Information
Jacqueline G. O'Boyle
(212) 659-9208

Cynara Maceda
(212) 659-8537

Recruiting Patients: Yes